1. Roberts, J. N., C. Karvonen, K. Graham, M. Weinfeld, A. A. Joy, M. Koebel, D. Morris, P. J. Robson, R. N. Johnston and N. T. Brockton (accepted for publication). Driving population metrics into biobanking quality. F. Karimi-Busheri, Springer.

2. Albert, M., J. Bartlett, R. N. Johnston, B. Schacter and P. Watson (2014). Biobank bootstrapping: is biobank sustainability possible through cost recovery? Biopreserv Biobank 12(6): 374, 2014.

3. Matzke, L., S. Dee, J. Bartlett, S. Damaraju, K. Graham, R. Johnston, A. M. Mes-Masson, L. Murphy, L. Shepherd, B. Schacter, et al. (2014). A practical tool for modeling biospecimen user fees. Biopreserv Biobank 12(4): 234, 2014.

4. Ogbogu, U., S. Burningham, A. Ollenberger, K. Calder, L. Du, K. El Emam, R. Hyde-Lay, R. Isasi, Y. Joly, I. Kerr, et al. (2014). Policy recommendations for addressing privacy challenges associated with cell-based research and interventions. BMC Med Ethics 15: 7, 2014.

5. Watson, P. H., S. Y. Nussbeck, C. Carter, S. O'Donoghue, S. Cheah, L. A. Matzke, R. O. Barnes, J. Bartlett, J. Carpenter, W. E. Grizzle, et al. (2014). A framework for biobank sustainability. Biopreserv Biobank 12(1): 60, 2014.

6. Barnes, R., M. Albert, S. Damaraju, J. de Sousa-Hitzler, S. Kodeeswaran, A. M. Mes-Masson, P. Watson and B. Schacter (2013). Generating a Comprehensive Set of Standard Operating Procedures for a Biorepository Network – The CTRNet Experience. Biopreserv Biobank: (in Press), 2013.

7. Le Page, C., M. Köbel, M. De Ladurantaye, K. Rahimi, J. Madore, S. Babinszky, D. Bachvarov, M. Bachvarov, M.-C. Beauchamp, C. E. Cass, et al. (2013). Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. Biopreserv Biobank 11(2): 83, 2013.

8. Ogbogu, U. and S. Burningham (2013). Privacy Protection and Genetic Research: Where does the public interest lie? Alberta Law Review, 2013.

9. Caulfield, T., C. Rachul and E. Nelson (2012). Biobanking, Consent, and Control: A Survey of Albertans on Key Research Ethics Issues. Biopreserv Biobank 10(5): 433, 2012.

10. Master, Z., E. Nelson, B. Murdoch and T. Caulfield (2012). Biobanks, consent and claims of consensus. Nat Methods 9(9): 885, 2012.

11. Matzke, L. A., S. O’Donoghue, R. O. Barnes, H. Daudt, S. Cheah, A. Suggitt, J. Bartlett, S. Damaraju, R. Johnston, L. Murphy, et al. (2012). Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet). Biopreserv Biobank 10(5): 426, 2012.

12. Rachul, C., A. McGuire and T. Caulfield (2012). Public Perceptions and Biobanking: What does the Research Really Say? Studies in Ethics, Law and Technology, 2012.

13. Borugian, M. J., P. Robson, I. Fortier, L. Parker, J. McLaughlin, B. M. Knoppers, K. Bedard, R. P. Gallagher, S. Sinclair, V. Ferretti, et al. (2010). The Canadian Partnership for Tomorrow Project: building a pan-Canadian research platform for disease prevention. CMAJ 182(11): 1197, 2010.

14. Damaraju, S., A. Driga, L. Cook, K. Calder, K. Graham, K. Dabbs, H. Steed, R. Berendt, J. R. Mackey and C. E. Cass (2012). Considerations on Dealing with Tissues and Cell Samples (Including Tissue Banking). Comprehensive Sampling and Sample Preparation L. Pawliszyn, X. C. Le, X.-F. Li and H. K. Lee. Oxford, UK, Elsevier, Academic Press. 3: 21.

1. Al Bashir, S., M. Alshalalfa, S. A. Hegazy, M. Dolph, B. Donnelly and T. A. Bismar (2014). Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis. J Hematol Oncol 7: 21, 2014.

2. Albert, M., J. Bartlett, R. N. Johnston, B. Schacter and P. Watson (2014). Biobank bootstrapping: is biobank sustainability possible through cost recovery? Biopreserv Biobank 12(6): 374, 2014.

3. Csizmadi, I., L. E. Kelemen, T. Speidel, Y. Yuan, L. C. Dale, C. M. Friedenreich and P. J. Robson (2014). Are physical activity levels linked to nutrient adequacy? Implications for cancer risk. Nutr Cancer 66(2): 214, 2014.

4. De Vivo, I., J. Prescott, V. W. Setiawan, S. H. Olson, N. Wentzensen, J. Attia, A. Black, L. Brinton, C. Chen, L. S. Cook, et al. (2014). Genome-wide association study of endometrial cancer in E2C2. Hum Genet 133(2): 211, 2014.

5. Hamilton, T. D., D. Leugner, K. Kopciuk, E. Dixon, F. R. Sutherland and O. F. Bathe (2014). Identification of prognostic inflammatory factors in colorectal liver metastases. BMC Cancer 14: 542, 2014.

6. Kelemen, L. E., J. D. Brenton, C. Parkinson, C. W. H, A. M. Piskorz, I. Csizmadi and P. J. Robson (2014). Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women. PLoS One 9(5): e96542, 2014.

7. Kuppusamy, H., H. M. Ogmundsdottir, E. Baigorri, A. Warkentin, H. Steingrimsdottir, V. Haraldsdottir, M. J. Mant, J. Mackey, J. B. Johnston, S. Adamia, et al. (2014). Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer. PLoS One 9(6): e100691, 2014.

8. Marcato, P., C. A. Dean, R. Z. Liu, K. M. Coyle, M. Bydoun, M. Wallace, D. Clements, C. Turner, E. G. Mathenge, S. A. Gujar, et al. (2014). Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling. Mol Oncol, 2014.

9. Xu, B., L. H. Teng, S. D. Silva, K. Bijian, S. Al Bashir, S. Jie, M. Dolph, M. A. Alaoui-Jamali and T. A. Bismar (2014). The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. Cancer Med 3(1): 14, 2014.

10. Amankwah, E. K., C. M. Friedenreich, A. M. Magliocco, R. Brant, K. S. Courneya, T. Speidel, W. Rahman, A. R. Langley and L. S. Cook (2013). Anthropometric measures and the risk of endometrial cancer, overall and by tumor microsatellite status and histological subtype. Am J Epidemiol 177(12): 1378, 2013.

11. Amankwah, E. K., C. M. Friedenreich, A. M. Magliocco, R. Brant, T. Speidel, W. Rahman and L. S. Cook (2013). Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors. Cancer Epidemiol Biomarkers Prev 22(7): 1325, 2013.

12. Anglesio, M. S., S. Kommoss, M. C. Tolcher, B. Clarke, L. Galletta, H. Porter, S. Damaraju, S. Fereday, B. J. Winterhoff, S. E. Kalloger, et al. (2013). Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 229(1): 111, 2013.

13. Bastani, M., L. Vos, N. Asgarian, J. Deschenes, K. Graham, J. Mackey and R. Greiner (2013). A machine learned classifier that uses gene expression data to accurately predict estrogen receptor status. PLoS One 8(12): e82144, 2013.

14. Bojesen, S. E., K. A. Pooley, S. E. Johnatty, J. Beesley, K. Michailidou, J. P. Tyrer, S. L. Edwards, H. A. Pickett, H. C. Shen, C. E. Smart, et al. (2013). Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45(4): 371, 2013.

15. Burningham, S. (2013). Cell therapy research and innovation: Identifying the emerging privacy challenges. . Medical Law International, 2013.

16. Cook, L. S., H. E. Nelson, C. A. Stidley, Y. Dong, P. J. Round, E. K. Amankwah, A. M. Magliocco and C. M. Friedenreich (2013). Endometrial cancer and a family history of cancer. Gynecol Oncol 130(2): 334, 2013.

17. Davis, V. W., D. E. Schiller, D. Eurich, O. F. Bathe and M. B. Sawyer (2013). Pancreatic Ductal Adenocarcinoma is Associated with a Distinct Urinary Metabolomic Signature. Ann Surg Oncol 20 Suppl(3): S415, 2013.

18. Friedenreich, C. M., A. R. Langley, T. P. Speidel, D. C. Lau, K. S. Courneya, I. Csizmadi, A. M. Magliocco, Y. Yasui and L. S. Cook (2013). Case-control study of inflammatory markers and the risk of endometrial cancer. Eur J Cancer Prev 22(4): 374, 2013.

19. Hajiloo, M., B. Damavandi, M. Hooshsadat, S. Farzad, J. Mackey, C. E. Cass, R. Greiner and S. Damaraju (2013). Breast cancer prediction using genome wide single nucleotide polymorphism data. BMC Bioinformatics 14(Suppl 13): S3, 2013.

20. Hajiloo, M., Y. Sapkota, J. R. Mackey, P. Robson, R. Greiner and S. Damaraju (2013). ETHNOPRED: a novel machine learning method for accurate continental and sub-continental ancestry identification and population stratification correction. BMC Bioinformatics 14: 61, 2013.

21. Permuth-Wey, J., K. Lawrenson, H. C. Shen, A. Velkova, J. P. Tyrer, Z. Chen, H. Y. Lin, Y. A. Chen, Y. Y. Tsai, X. Qu, et al. (2013). Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun 4: 1627, 2013.

22. Pharoah, P. D., Y. Y. Tsai, S. J. Ramus, C. M. Phelan, E. L. Goode, K. Lawrenson, M. Buckley, B. L. Fridley, J. P. Tyrer, H. Shen, et al. (2013). GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 45(4): 362, 2013.

23. Sapkota, Y., S. Ghosh, R. Lai, B. P. Coe, C. E. Cass, Y. Yasui, J. R. Mackey and S. Damaraju (2013). Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence. PLoS One 8(1): e53850, 2013.

24. Sapkota, Y., J. R. Mackey, R. Lai, C. Franco-Villalobos, S. Lupichuk, P. J. Robson, K. Kopciuk, C. E. Cass, Y. Yasui and S. Damaraju (2013). Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility. PLoS One 8(6): e64896, 2013.

25. Sapkota, Y., Y. Yasui, R. Lai, M. Sridharan, P. J. Robson, C. E. Cass, J. R. Mackey and S. Damaraju (2013). Identification of a breast cancer susceptibility locus at 4q31.22 using a genome-wide association study paradigm. PLoS One 8(5): e62550, 2013.

26. Setiawan, V. W., H. P. Yang, M. C. Pike, S. E. McCann, H. Yu, Y. B. Xiang, A. Wolk, N. Wentzensen, N. S. Weiss, P. M. Webb, et al. (2013). Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31(20): 2607, 2013.

27. Shen, H., B. L. Fridley, H. Song, K. Lawrenson, J. M. Cunningham, S. J. Ramus, M. S. Cicek, J. Tyrer, D. Stram, M. C. Larson, et al. (2013). Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 4: 1628, 2013.

28. Stretch, C., S. Khan, N. Asgarian, R. Eisner, S. Vaisipour, S. Damaraju, K. Graham, O. F. Bathe, H. Steed, R. Greiner, et al. (2013). Effects of sample size on differential gene expression, rank order and prediction accuracy of a gene signature. PLoS One 8(6): e65380, 2013.

29. Woolcott, C. G., K. S. Courneya, N. F. Boyd, M. J. Yaffe, A. McTiernan, R. Brant, C. A. Jones, F. Z. Stanczyk, T. Terry, L. S. Cook, et al. (2013). Longitudinal Changes in IGF-I and IGFBP-3, and Mammographic Density among Postmenopausal Women. Cancer Epidemiol Biomarkers Prev 22(11): 21164, 2013.

30. Woolcott, C. G., K. S. Courneya, N. F. Boyd, M. J. Yaffe, A. McTiernan, R. Brant, C. A. Jones, F. Z. Stanczyk, T. Terry, L. S. Cook, et al. (2013). Association between sex hormones, glucose homeostasis, adipokines, and inflammatory markers and mammographic density among postmenopausal women. Breast Cancer Res Treat 139(1): 255, 2013.

31. Caulfield, T., C. Rachul and E. Nelson (2012). Biobanking, Consent, and Control: A Survey of Albertans on Key Research Ethics Issues. Biopreserv Biobank 10(5): 433, 2012.

32. Courneya, K. S., J. K. Vallance, S. N. Culos-Reed, M. L. McNeely, G. J. Bell, J. R. Mackey, Y. Yasui, Y. Yuan, C. E. Matthews, D. C. Lau, et al. (2012). The Alberta moving beyond breast cancer (AMBER) cohort study: a prospective study of physical activity and health-related fitness in breast cancer survivors. BMC Cancer 12: 525, 2012.

33. Davis, V. W., D. E. Schiller, D. Eurich and M. B. Sawyer (2012). Urinary metabolomic signature of esophageal cancer and Barrett's esophagus. World J Surg Oncol 10: 271, 2012.

34. Dechaphunkul, A., M. Phukaoloun, K. Kanjanapradit, K. Graham, S. Ghosh, C. Santos and J. R. Mackey (2012). Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. Int J Breast Cancer 2012: 290854, 2012.

35. Friedenreich, C. M., A. R. Langley, T. P. Speidel, D. C. Lau, K. S. Courneya, I. Csizmadi, A. M. Magliocco, Y. Yasui and L. S. Cook (2012). Case-control study of markers of insulin resistance and endometrial cancer risk. Endocr Relat Cancer 19(6): 785, 2012.

36. Friedenreich, C. M., H. K. Neilson, C. G. Woolcott, Q. Wang, F. Z. Stanczyk, A. McTiernan, C. A. Jones, M. L. Irwin, Y. Yasui and K. S. Courneya (2012). Inflammatory marker changes in a yearlong randomized exercise intervention trial among postmenopausal women. Cancer Prev Res (Phila) 5(1): 98, 2012.

37. Hurvitz, S. A., D. J. Betting, H. M. Stern, E. Quinaux, J. Stinson, S. Seshagiri, Y. Zhao, M. Buyse, J. Mackey, A. Driga, et al. (2012). Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 18(12): 3478, 2012.

38. Liu, R. Z., K. Graham, D. D. Glubrecht, R. Lai, J. R. Mackey and R. Godbout (2012). A fatty acid-binding protein 7/RXRbeta pathway enhances survival and proliferation in triple-negative breast cancer. J Pathol 228(3): 310, 2012.

39. Sapkota, Y., P. Robson, R. Lai, C. E. Cass, J. R. Mackey and S. Damaraju (2012). A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility. Eur J Hum Genet 20(6): 682, 2012.

40. Shah, S. P., A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, et al. (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403): 395, 2012.

41. Stretch, C., T. Eastman, R. Mandal, R. Eisner, D. S. Wishart, M. Mourtzakis, C. M. Prado, S. Damaraju, R. O. Ball, R. Greiner, et al. (2012). Prediction of skeletal muscle and fat mass in patients with advanced cancer using a metabolomic approach. J Nutr 142(1): 14, 2012.

42. Tan, B. H., T. Fladvad, T. P. Braun, A. Vigano, F. Strasser, D. A. Deans, R. J. Skipworth, T. S. Solheim, S. Damaraju, J. A. Ross, et al. (2012). P-selectin genotype is associated with the development of cancer cachexia. EMBO Mol Med 4(6): 462, 2012.

43. Zhang, J., A. J. Gill, J. D. Issacs, B. Atmore, A. Johns, L. W. Delbridge, R. Lai and T. P. McMullen (2012). The Wnt/beta-catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. Hum Pathol 43(7): 1044, 2012.

44. Zhang, J., P. Wang, M. Dykstra, P. Gelebart, D. Williams, R. Ingham, E. E. Adewuyi, R. Lai and T. McMullen (2012). Platelet-derived growth factor receptor-alpha promotes lymphatic metastases in papillary thyroid cancer. J Pathol 228(2): 241, 2012.

45. Amankwah, E. K., Q. Wang, J. M. Schildkraut, Y. Y. Tsai, S. J. Ramus, B. L. Fridley, J. Beesley, S. E. Johnatty, P. M. Webb, G. Chenevix-Trench, et al. (2011). Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS One 6(5): e19642, 2011.

46. Beesley, J., H. A. Pickett, S. E. Johnatty, A. M. Dunning, X. Chen, J. Li, K. Michailidou, Y. Lu, D. N. Rider, R. T. Palmieri, et al. (2011). Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One 6(9): e24987, 2011.

47. Friedenreich, C. M., R. K. Biel, D. C. Lau, I. Csizmadi, K. S. Courneya, A. M. Magliocco, Y. Yasui and L. S. Cook (2011). Case-control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 20(11): 2384, 2011.

48. Friedenreich, C. M., H. K. Neilson, C. G. Woolcott, A. McTiernan, Q. Wang, R. Ballard-Barbash, C. A. Jones, F. Z. Stanczyk, R. F. Brant, Y. Yasui, et al. (2011). Changes in insulin resistance indicators, IGFs, and adipokines in a year-long trial of aerobic exercise in postmenopausal women. Endocr Relat Cancer 18(3): 357, 2011.

49. Friedenreich, C. M., H. K. Neilson, C. G. Woolcott, Q. Wang, Y. Yasui, R. F. Brant, F. Z. Stanczyk, K. L. Campbell and K. S. Courneya (2011). Mediators and moderators of the effects of a year-long exercise intervention on endogenous sex hormones in postmenopausal women. Cancer Causes Control 22(10): 1365, 2011.

50. Germain, D. R., K. Graham, D. D. Glubrecht, J. C. Hugh, J. R. Mackey and R. Godbout (2011). DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Res Treat 127(1): 53, 2011.

51. Liu, R. Z., K. Graham, D. D. Glubrecht, D. R. Germain, J. R. Mackey and R. Godbout (2011). Association of FABP5 expression with poor survival in triple-negative breast cancer: implication for retinoic acid therapy. Am J Pathol 178(3): 997, 2011.

52. Lurie, G., L. R. Wilkens, P. J. Thompson, Y. B. Shvetsov, R. K. Matsuno, M. E. Carney, R. T. Palmieri, A. H. Wu, M. C. Pike, C. L. Pearce, et al. (2011). Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium. PLoS One 6(6): e20703, 2011.

53. Pharoah, P. D., R. T. Palmieri, S. J. Ramus, S. A. Gayther, I. L. Andrulis, H. Anton-Culver, N. Antonenkova, A. C. Antoniou, D. Goldgar, M. S. Beattie, et al. (2011). The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 17(11): 3742, 2011.

54. Prado, C. M., I. S. Lima, V. E. Baracos, R. R. Bies, L. J. McCargar, T. Reiman, J. R. Mackey, M. Kuzma, V. L. Damaraju and M. B. Sawyer (2011). An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67(1): 93, 2011.

55. Sehrawat, B., M. Sridharan, S. Ghosh, P. Robson, C. E. Cass, J. R. Mackey, R. Greiner and S. Damaraju (2011). Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility. Hum Genet 130(4): 529, 2011.

56. Tamburrini, A. L., C. G. Woolcott, N. F. Boyd, M. J. Yaffe, T. Terry, Y. Yasui, C. A. Jones, S. B. Patten, K. S. Courneya and C. M. Friedenreich (2011). Associations between mammographic density and serum and dietary cholesterol. Breast Cancer Res Treat 125(1): 181, 2011.

57. Zhang, J., A. Gill, B. Atmore, A. Johns, L. Delbridge, R. Lai and T. McMullen (2011). Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. Int J Clin Exp Pathol 4(4): 356, 2011.

58. Bolton, K. L., J. Tyrer, H. Song, S. J. Ramus, M. Notaridou, C. Jones, T. Sher, A. Gentry-Maharaj, E. Wozniak, Y. Y. Tsai, et al. (2010). Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42(10): 880, 2010.

59. Craik, A. C., R. A. Veldhoen, M. Czernick, T. W. Buckland, K. Kyselytzia, S. Ghosh, R. Lai, S. Damaraju, D. A. Underhill, J. R. Mackey, et al. (2010). The BH3-only protein Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism. Oncogene 29(39): 5381, 2010.

60. De Ruysscher, D., D. Severin, E. Barnes, M. Baumann, R. Bristow, V. Gregoire, T. Holscher, T. Veninga, A. Polanski, E. B. van Veen, et al. (2010). First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II. Radiother Oncol 97(1): 36, 2010.

61. Friedenreich, C. M., C. G. Woolcott, A. McTiernan, R. Ballard-Barbash, R. F. Brant, F. Z. Stanczyk, T. Terry, N. F. Boyd, M. J. Yaffe, M. L. Irwin, et al. (2010). Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol 28(9): 1458, 2010.

62. Goode, E. L., G. Chenevix-Trench, H. Song, S. J. Ramus, M. Notaridou, K. Lawrenson, M. Widschwendter, R. A. Vierkant, M. C. Larson, S. K. Kjaer, et al. (2010). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42(10): 874, 2010.

63. Johnatty, S. E., J. Beesley, X. Chen, S. Macgregor, D. L. Duffy, A. B. Spurdle, A. deFazio, N. Gava, P. M. Webb, M. A. Rossing, et al. (2010). Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot". PLoS Genet 6(7): e1001016, 2010.

64. Slupsky, C. M., H. Steed, T. H. Wells, K. Dabbs, A. Schepansky, V. Capstick, W. Faught and M. B. Sawyer (2010). Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 16(23): 5835, 2010.

65. Korenberg, M. J., B. J. Dicken, S. Damaraju, K. Graham and C. E. Cass (2009). Predicting node positivity in gastric cancer from gene expression profiles. Biotechnol Lett 31(9): 1381, 2009.

66. Gong, Y., N. Wang, F. Wu, C. E. Cass, S. Damaraju, J. R. Mackey and L. Li (2008). Proteome profile of human breast cancer tissue generated by LC-ESI-MS/MS combined with sequential protein precipitation and solubilization. J Proteome Res 7(8): 3583, 2008.

67. Damaraju, S., D. Murray, J. Dufour, D. Carandang, S. Myrehaug, G. Fallone, C. Field, R. Greiner, J. Hanson, C. E. Cass, et al. (2006). Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12(8): 2545, 2006.

68. Dicken, B. J., K. Graham, S. M. Hamilton, S. Andrews, R. Lai, J. Listgarten, G. S. Jhangri, L. D. Saunders, S. Damaraju and C. Cass (2006). Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg 243(1): 64, 2006.

69. Damaraju, S., J. Zhang, F. Visser, T. Tackaberry, J. Dufour, K. M. Smith, M. Slugoski, M. W. Ritzel, S. A. Baldwin, J. D. Young, et al. (2005). Identification and functional characterization of variants in human concentrative nucleoside transporter 3, hCNT3 (SLC28A3), arising from single nucleotide polymorphisms in coding regions of the hCNT3 gene. Pharmacogenet Genomics 15(3): 173, 2005.

70. Unryn, B. M., L. S. Cook and K. T. Riabowol (2005). Paternal age is positively linked to telomere length of children. Aging Cell 4(2): 97, 2005.

71. Listgarten, J., S. Damaraju, B. Poulin, L. Cook, J. Dufour, A. Driga, J. Mackey, D. Wishart, R. Greiner and B. Zanke (2004). Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res 10(8): 2725, 2004.

72. Listgarten, J., K. Graham, S. Damaraju, C. Cass, J. Mackey and B. Zanke (2003). Clinically validated benchmarking of normalisation techniques for two-colour oligonucleotide spotted microarray slides. Appl Bioinformatics 2(4): 219, 2003.

73. Damaraju, S., M. Sawyer and B. Zanke (2002). Genomic approaches to clinical drug resistance. Cancer Treat Res 112: 347, 2002.